NeuBase Therapeutics
(NASDAQ) NBSE
This security has been delisted. This page is retained for historical reference.
NBSE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowNBSE Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-88.62%
Return on Capital
-114.15%
Return on Assets
-104.71%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
-$854.00K
Operating Income
-$15.27M
EBITDA
-$11.89M
Operating Cash Flow
-$14.78M
Capital Expenditure
-$63.30K
Free Cash Flow
-$14.85M
Cash & ST Invst.
$12.57M
Total Debt
$5.34M
NeuBase Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$250.00K
+25.4%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
37
N/A
Net Income
-$1.82M
+76.1%
EBITDA
-$1.57M
+78.5%
Quarterly Fundamentals
Total Cash
$12.57M
-45.7%
Total Debt
$5.34M
-11.0%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
+100.0%
Long Term Debt
$4.83M
-9.4%
Short Term Debt
$500.82K
-24.2%
Return on Assets
-1.05%
N/A
Return on Invested Capital
-1.17%
N/A
Free Cash Flow
-$2.00M
+70.0%
Operating Cash Flow
-$2.00M
+69.8%